In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

(Reuters) -Haleon posted an unexpected drop in third-quarter revenue on Thursday, hurt by a weak demand for its painkiller in ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

GSK cuts 2024 vaccine sales forecast for second time this year Strong specialty medicines offset lower vaccine sales - CEO Q3 EPS beats market expectations Shares down 3.9% at 0958 GMT Oct 30 ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s intraday trade. The stock rose after the company reported its second quarter ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of ...

U.S. Q3 GDP growth revised up to 2.9% on stronger consumer spending By Investing.com - Nov 30, 2022 1 By Geoffrey Smith Investing.com -- The U.S. economy grew faster than first thought in the ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...